Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Stewart

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Plos Clinical Trials|November 25, 2006
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trialMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
BMJ Open|April 1, 2019
The ART of conversation: feasibility and acceptability of a pilot peer intervention to help transition complex HIV-positive people from hospital to communityAndrew David Eaton, Soo Chan Carusone, Shelley L Craig, et al.
Frontiers in Cellular and Infection Microbiology|December 16, 2020
<i>Plasmodium falciparum</i> DHFR and DHPS Mutations Are Associated With HIV-1 Co-Infection and a Novel DHPS Mutation I504T Is Identified in Western KenyaBrandi K Torrevillas, Sarah M Garrison, Alexander J McKeeken, et al.
Vaccine|August 15, 2006
Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02AV Ann Stewart, Shannon M McGrath, Douglas S Walsh, et al.
Vaccine|May 6, 2008
Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in miceJoseph P Shott, Shannon M McGrath, Maria Grazia Pau, et al.
Vaccine|April 1, 2006
Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02ADouglas S Walsh, Montip Gettayacamin, Wolfgang W Leitner, et al.
Infection and Immunity|February 20, 2007
Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine aloneV Ann Stewart, Shannon M McGrath, Patrice M Dubois, et al.
The Journal of Infectious Diseases|July 3, 2009
Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protectionKent E Kester, James F Cummings, Opokua Ofori-Anyinam, et al.
Vaccine|January 4, 2006
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western KenyaJosé A Stoute, Joash Gombe, Mark R Withers, et al.
Plos One|August 4, 2009
Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission areaMark E Polhemus, Shon A Remich, Bernhards R Ogutu, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Plos Clinical Trials|November 25, 2006
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trialMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
BMJ Open|April 1, 2019
The ART of conversation: feasibility and acceptability of a pilot peer intervention to help transition complex HIV-positive people from hospital to communityAndrew David Eaton, Soo Chan Carusone, Shelley L Craig, et al.
Frontiers in Cellular and Infection Microbiology|December 16, 2020
<i>Plasmodium falciparum</i> DHFR and DHPS Mutations Are Associated With HIV-1 Co-Infection and a Novel DHPS Mutation I504T Is Identified in Western KenyaBrandi K Torrevillas, Sarah M Garrison, Alexander J McKeeken, et al.
Vaccine|August 15, 2006
Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02AV Ann Stewart, Shannon M McGrath, Douglas S Walsh, et al.
Vaccine|May 6, 2008
Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in miceJoseph P Shott, Shannon M McGrath, Maria Grazia Pau, et al.
Vaccine|April 1, 2006
Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02ADouglas S Walsh, Montip Gettayacamin, Wolfgang W Leitner, et al.
Infection and Immunity|February 20, 2007
Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine aloneV Ann Stewart, Shannon M McGrath, Patrice M Dubois, et al.
The Journal of Infectious Diseases|July 3, 2009
Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protectionKent E Kester, James F Cummings, Opokua Ofori-Anyinam, et al.
Vaccine|January 4, 2006
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western KenyaJosé A Stoute, Joash Gombe, Mark R Withers, et al.
Plos One|August 4, 2009
Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission areaMark E Polhemus, Shon A Remich, Bernhards R Ogutu, et al.
Pageof 9